title: Interaction of cocaine-, benztropine-, and GBR12909-like compounds with wild-type and mutant human dopamine transporters: molecular features that differentially determine antagonist-binding properties.
abstract: The widely abused psychostimulant cocaine is thought to elicit its reinforcing effects primarily via inhibition of the neuronal dopamine transporter (DAT). However, not all DAT inhibitors share cocaine's behavioral profile, despite similar or greater affinity for the DAT. This may be due to differential molecular interactions with the DAT. Our previous work using transporter mutants with altered conformational equilibrium (W84L and D313N) indicated that benztropine and GBR12909 interact with the DAT in a different manner than cocaine. Here, we expand upon these previous findings, studying a number of structurally different DAT inhibitors for their ability to inhibit [(3)H]CFT binding to wild-type, W84L and D313N transporters. We systematically tested structural intermediates between cocaine and benztropine, structural hybrids of benztropine and GBR12909 and a number of other structurally heterologous inhibitors. Derivatives of the stimulant desoxypipradrol (2-benzhydrylpiperidine) exhibited a cocaine-like binding profile with respect to mutation, whereas compounds possessing the diphenylmethoxy moiety of benztropine and GBR12909 were dissimilar to cocaine-like compounds. In tests with specific isomers of cocaine and tropane analogues, compounds with 3alpha stereochemistry tended to exhibit benztropine-like binding, whereas those with 3beta stereochemistry were more cocaine-like. Our results point to the importance of specific molecular features--most notably the presence of a diphenylmethoxy moiety--in determining a compound's binding profile. This study furthers the concept of using DAT mutants to differentiate cocaine-like inhibitors from atypical inhibitors in vitro. Further studies of the molecular features that define inhibitor-transporter interaction could lead to the development of DAT inhibitors with differential clinical utility.
authors.affiliation: Department of Psychiatry, New York University School of Medicine, New York, New York, USA.
authors.forename: Kyle C
authors.initials: KC
authors.lastname: Schmitt
authors.forename: Juan
authors.initials: J
authors.lastname: Zhen
authors.forename: Prashant
authors.initials: P
authors.lastname: Kharkar
authors.forename: Manoj
authors.initials: M
authors.lastname: Mishra
authors.forename: Nianhang
authors.initials: N
authors.lastname: Chen
authors.forename: Aloke K
authors.initials: AK
authors.lastname: Dutta
authors.forename: Maarten E A
authors.initials: ME
authors.lastname: Reith
mesh_terms: D000818:Animals; D001216:Asparagine / Q000235:genetics; D001224:Aspartic Acid / Q000235:genetics; D001590:Benztropine / Q000737:chemistry / Q000494:pharmacology; D001667:Binding, Competitive / Q000187:drug effects*; D002461:Cell Line, Transformed; D003042:Cocaine / Q000031:analogs & derivatives / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D050483:Dopamine Plasma Membrane Transport Proteins / Q000235:genetics*; D018765:Dopamine Uptake Inhibitors / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology*; D004347:Drug Interactions; D006801:Humans; D007930:Leucine / Q000235:genetics; D008958:Models, Molecular; D009154:Mutation / Q000235:genetics*; D010879:Piperazines / Q000737:chemistry / Q000494:pharmacology; D011485:Protein Binding / Q000187:drug effects; D017434:Protein Structure, Tertiary; D012964:Sodium / Q000378:metabolism; D013329:Structure-Activity Relationship; D014162:Transfection / Q000379:methods; D014316:Tritium / Q000378:metabolism; D014364:Tryptophan / Q000235:genetics
chemical_list: D050483:Dopamine Plasma Membrane Transport Proteins; D018765:Dopamine Uptake Inhibitors; D010879:Piperazines; D014316:Tritium; D001590:Benztropine; D001224:Aspartic Acid; C021279:(1R-(exo,exo))-3-(4-fluorophenyl)-8-methyl-8- azabicyclo(3.2.1)octane-2-carboxylic acid, methyl ester; D001216:Asparagine; D014364:Tryptophan; C043425:vanoxerine; D012964:Sodium; D007930:Leucine; D003042:Cocaine
references.citation: Nature. 2007 Aug 23;448(7156):952-6
references.pmid: 17687333
references.citation: Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12761-6
references.pmid: 17652169
references.citation: J Neurochem. 2006 Sep;98(5):1531-40
references.pmid: 16923164
references.citation: J Neurochem. 2001 May;77(4):1116-27
references.pmid: 11359877
references.citation: Nat Neurosci. 2008 Jul;11(7):780-9
references.pmid: 18568020
references.citation: J Neurosci. 2001 Mar 1;21(5):1787-94
references.pmid: 11222668
references.citation: Biochem Pharmacol. 2005 Aug 1;70(3):461-9
references.pmid: 15950948
references.citation: J Neurochem. 2004 May;89(3):750-65
references.pmid: 15086531
references.citation: J Biol Chem. 2007 Oct 5;282(40):29441-7
references.pmid: 17698848
references.citation: J Pharmacol Exp Ther. 2005 Aug;314(2):575-83
references.pmid: 15879005
references.citation: Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9333-8
references.pmid: 16754872
references.citation: Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1683-8
references.pmid: 11818545
references.citation: Eur J Pharmacol. 2004 Dec 3;506(1):17-26
references.pmid: 15588620
references.citation: J Biol Chem. 2007 Mar 23;282(12):8915-25
references.pmid: 17255098
references.citation: J Pharmacol Exp Ther. 2007 Nov;323(2):720-9
references.pmid: 17673606
references.citation: Nature. 2005 Sep 8;437(7056):215-23
references.pmid: 16041361
references.citation: Eur J Pharmacol. 1995 Aug 4;281(2):195-203
references.pmid: 7589207
references.citation: Bioorg Med Chem Lett. 2005 Dec 15;15(24):5488-93
references.pmid: 16202585
references.citation: Eur J Pharmacol. 2003 Oct 31;479(1-3):93-106
references.pmid: 14612141
references.citation: Biophys J. 2007 Nov 15;93(10):3627-39
references.pmid: 17704152
references.citation: Pflugers Arch. 2004 Feb;447(5):519-31
references.pmid: 12719981
references.citation: J Neurosci. 2005 Feb 23;25(8):1889-93
references.pmid: 15728828
references.citation: J Pharmacol Exp Ther. 2006 Jun;317(3):1088-96
references.pmid: 16478825
references.citation: J Med Chem. 1992 Jan;35(1):135-40
references.pmid: 1732520
references.citation: J Biol Chem. 2006 Jan 27;281(4):2012-23
references.pmid: 16272152
references.citation: Mol Pharmacol. 2008 Apr;73(4):1141-50
references.pmid: 18216182
references.citation: J Biol Chem. 1999 Dec 24;274(52):36928-34
references.pmid: 10601246
references.citation: Nature. 1996 Feb 15;379(6566):606-12
references.pmid: 8628395
references.citation: Neuropsychopharmacology. 2006 Feb;31(2):351-62
references.pmid: 15957006
references.citation: J Biol Chem. 2001 Aug 3;276(31):29012-8
references.pmid: 11395483
references.citation: Science. 2007 Sep 7;317(5843):1390-3
references.pmid: 17690258
references.citation: Synapse. 2005 Nov;58(2):72-94
references.pmid: 16088952
references.citation: Mol Pharmacol. 2000 Dec;58(6):1581-92
references.pmid: 11093799
references.citation: Mol Pharmacol. 2008 Mar;73(3):813-23
references.pmid: 17978168
references.citation: Mol Pharmacol. 1999 Aug;56(2):434-47
references.pmid: 10419565
references.citation: Addict Behav. 2004 Sep;29(7):1439-64
references.pmid: 15345275
references.citation: Biochem Pharmacol. 1986 Apr 1;35(7):1123-9
references.pmid: 3964292
references.citation: Pharmacol Biochem Behav. 1982 Nov;17(5):901-4
references.pmid: 6817350
references.citation: Biochem Pharmacol. 1973 Dec 1;22(23):3099-108
references.pmid: 4202581
references.citation: Proteins. 2008 Feb 15;70(3):1033-46
references.pmid: 17847094
references.citation: J Neurochem. 2004 May;89(4):853-64
references.pmid: 15140185